Society for Translational Oncology Fellows’ Forum (STOFF)

Society for Translational Oncology Fellows' Forum (STOFF) is an intensive 3-day forum that brings together 25 fellows and junior cancer researchers within 5 years of training completion from leading medical, surgical, radiation, and pediatric oncology groups and subspecialty fellowships to educate these rising stars on issues around and barriers to successful translational cancer research. 

Announcing our 2023 STOFF Fellows

Amir Ameri, MD, Johns Hopkins Medicine
Eric Bent, PhD, Harvard Medical School
Rahul Bhansali, MD, Hospital of the University of Pennsylvania
Julia Blanter, MD, Icahn School of Medicine at Mount Sinai
Raju Chelluri, MD, MS, Fox Chase Cancer Center
Heidy Cos Felipe, MD, Washington University in St Louis
Ayse Ece Cali Daylan, MD, PhD, Montefiore Medical Center
Kunal Desai, MD, MBA, MS, University of Chicago
Oluwadunni Emiloju, MDDS, MS, Mayo Clinic College of Medicine

    Takeo Fujii, MD, MPH, Northwell Health Cancer Institute | Cold Spring Harbor Laboratory
    Yiduo Ian Hu, MD, PhD, BSc, Yale School of Medicine
    Kohsuke Isomoto, MD, PhD, Department of Medical Oncology, Kindai University, Faculty of Medicine
    Adriana Kahn, MD, Yale University
    Asuka Kawachi, MD, National Cancer Center Hospital (NCCH)
    Katie N. Lee, MD, PhD, Harvard Medical School
    Abu-Sayeef Mirza, MD, MPH, FACP, Yale University
    Tarek H. Mouhieddine, MD, Icahn School of Medicine at Mount Sinai

      Curt Perry, MD, PhD, Yale New Haven Hospital
      Dionisia Marie Quiroga, DO, PhD, Ohio State University
      Nathaniel Robinson, MD, Yale School of Medicine
      Joshua Smith, MD, University of Michigan
      Masahiro Uni, MD, PhD, Memorial Sloan Kettering Cancer Center
      Norihiro Yamaguchi, MD, MPH, PhD, National Institutes of Health
      James Yu, MD, University of South Florida
      Yumeng Zhang, MD, University of South Florida


        This annual forum receives praise from alumni and faculty for its focused, practical, and personal approach to preparing oncologists to conduct cancer drug research. It provides guidance to oncology fellows and junior cancer researchers regarding how to apply translational research findings in tumor biology to improve patient outcomes. 

        The broad-based curriculum covers a range of topics related to new drug development. In addition, it addresses key issues that early-career oncologists may face, such as identifying an important research topic and organizing a project; working closely with industry and aligning objectives; working within the legal framework of US Food & Drug Administration requirements; and applying guidance regarding conflicts of interest. 

        One of the highlights of STOFF and what sets it apart from other programs is the one-on-one engagement. With a faculty to student ratio of 1:1.5, trainees have unique opportunities to connect with other scientists and clinicians regarding translational research efforts that benefit from multidisciplinary and interprofessional investigation. 

        The faculty features prominent research scientists, clinical investigators, industry representatives, and biotech investors who serve as mentors to attendees and will also lead discussions on the following topics: 

        • Preclinical and clinical evaluation 
        • Validation of targets and biomarkers
        • Confirmation of mechanism of action and resistance in clinical trials 
        • Racial and age-related disparities in clinical trials 
        • Mechanics of grant-writing 
        • Guidelines for good basic research 
        • Approaches to establishing networks of peer oncologists 

        “Educating young oncologists in the field of clinical and translational research is an investment in the future and is likely to impact the quality of cancer patient care for years to come,” said Bruce A. Chabner (Massachusetts General Hospital/Harvard Medical School), founder of STOFF, more than two decades ago. Since then, many of the 665+ alumni have earned significant acclaim in their careers and in drug development. 

        Upon completion of this training, participants will be able to: 

        • Identify the importance of translational research and define its value in clinical medicine. 
        • Describe the process of drug development in oncology. 
        • Apply the mechanics of grant writing and guidelines for sound research practices.

        STOFF Summaries STOFF Interview Feature


        STOFF 2024 Button

        Privacy Policy | Terms of Use | Contact Us

        Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization.